We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
- Britecyte has secured a $1 million clinical grant from the Maryland Stem Cell Research Fund to advance its Adipose Tissue Allograft (BRC-OA) therapy for osteoarthritis treatment. - The FDA has accepted the company's Investigational New Drug application for a First-in-Human Phase 1/2a clinical study targeting knee osteoarthritis. - The multicenter, randomized, single-blind, dose-finding study represents a potential breakthrough for a disease with no approved disease-modifying treatments. - The collaboration between Britecyte, Amarex, and Regenerative Orthopedics & Sports Medicine aims to develop a therapy that could reverse osteoarthritis progression.
